UCSF Multiple Sclerosis Center
Welcome,         Profile    Billing    Logout  
 5 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cree, Bruce
IMPACT MS, NCT04466150: Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Active, not recruiting
4
30
US
Ocrelizumab, Ocrevus
University of California, San Francisco, Genentech, Inc., Valhalla Foundation
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
12/26
07/27
NCT06451159: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Recruiting
1
10
US
KYV-101 (Biological) - 0.33 ×10^8 cells, CAR T-cell therapy, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
Bruce Cree, Kyverna Therapeutics
Progressive Multiple Sclerosis
06/26
06/27
Gelfand, Jeffrey
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Recruiting
1/2
10
US
NRTX-1001, GABA-secreting interneurons
Neurona Therapeutics
Epilepsy, Temporal Lobe
07/26
07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting
1/2
40
US
NRTX-1001, GABA-secreting interneurons, Sham Comparator
Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
05/25
05/26

Download Options